The New York Stock Exchange (NYSE) has spent about a year testing Avalanche blockchain technology as it develops infrastructure for a tokenized securities platform. The platform aims to support tokenized U.S. stocks and ETFs with blockchain-based settlement, pending regulatory approval. NYSE has built a close working relationship with Ava Labs, the developer of Avalanche, but has not yet selected a blockchain for its system, which is designed to work with multiple networks. The project includes features like continuous trading, immediate settlement, fractional shares, and stablecoin funding, and is part of a broader move by NYSE's parent company, Intercontinental Exchange (ICE), to build tokenized securities infrastructure with partners like tZERO and Securitize. Recent SEC exemptions for tokenized stock trading could accelerate market adoption, though major exchanges' timelines remain uncertain.
The New York Stock Exchange's year-long testing of Avalanche technology is notable context for readers. For those tracking major cryptocurrencies on Pluang, 46 of 50 rose today. Notable movers include DOT at Rp20.185 with a 9.96% increase and 75% buy order activity, ONE at Rp31 with a 9.17% rise but 98% sell orders, and ETC at Rp143.151 up 9.00% with 99% buy orders. This data is as of Sep 18, 2026 21:36 WIB.
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
Dune has completed a SOC 2 Type II examination with no exceptions, providing institutional clients with verified assurance of its data security standards. This milestone comes as tokenized real-world assets doubled to $32.6 billion and stablecoin mar...
Northern Discovery Metals has finalized the acquisition of a 100% interest in the Cibola copper-gold project in British Columbia from Orogen Royalties. The project covers about 3,567 hectares near Houston, BC, in a region known for porphyry copper de...
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
